AtriCure (ATRC) Presents At 40th Annual J.P. Morgan Healthcare Conference

Market Opportunity - AtriCure addresses a large global Afib market, with over 33 million patients worldwide[12, 60] - The US market opportunity is estimated at over $3 billion annually, while the international market presents a $2 billion+ opportunity[14] - The company estimates that the standalone Afib market includes over 3 million patients, with less than 1% currently treated[21] Financial Performance & Growth - The company's revenue guidance for 2022 is between $315 million and $330 million, representing a year-over-year growth of 15-20%[54] - Historically, AtriCure has demonstrated strong revenue growth, with a 5-year organic revenue CAGR of approximately 15%[54] - U S AtriClip has a 5-Year historical organic revenue CAGR ~32%[54] Product Portfolio & Clinical Evidence - The company's AtriClip device has over 300,000 units sold to date[24, 60] - The CONVERGE trial demonstrated superior outcomes with the hybrid Convergent procedure compared to endocardial catheter ablation alone in patients with drug-refractory long-standing persistent Afib, with a 29% differential improvement[29] - Cryo Nerve Block therapy accounted for approximately 8% of AtriCure's worldwide revenue in 2021, up from approximately 5% in 2020[45]